122 related articles for article (PubMed ID: 20591748)
1. Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy.
Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin JK; Lizarde J; Macedo JC; Ravera J; Tokita KM
Brachytherapy; 2011; 10(1):44-50. PubMed ID: 20591748
[TBL] [Abstract][Full Text] [Related]
2. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer.
Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin J; Lizarde J; Macedo J; Ravera J; Tokita KM
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):824-30. PubMed ID: 20510195
[TBL] [Abstract][Full Text] [Related]
3. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.
Prada PJ; Fernández J; Martinez AA; de la Rúa A; Gonzalez JM; Fernandez JM; Juan G
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):95-102. PubMed ID: 17707267
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric implications of an injection of hyaluronic acid for preserving the rectal wall in prostate stereotactic body radiation therapy.
Chapet O; Udrescu C; Tanguy R; Ruffion A; Fenoglietto P; Sotton MP; Devonec M; Colombel M; Jalade P; Azria D
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):425-32. PubMed ID: 24411613
[TBL] [Abstract][Full Text] [Related]
5. Prostate hypofractionated radiation therapy with injection of hyaluronic acid: acute toxicities in a phase 2 study.
Chapet O; Decullier E; Bin S; Faix A; Ruffion A; Jalade P; Fenoglietto P; Udrescu C; Enachescu C; Azria D
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):730-6. PubMed ID: 25752385
[TBL] [Abstract][Full Text] [Related]
6. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy.
Strom TJ; Wilder RB; Fernandez DC; Mellon EA; Saini AS; Hunt DC; Pow-Sang JM; Spiess PE; Sexton WJ; Poch MA; Biagioli MC
Radiother Oncol; 2014 Apr; 111(1):126-31. PubMed ID: 24746567
[TBL] [Abstract][Full Text] [Related]
7. Technique of Injection of Hyaluronic Acid as a Prostatic Spacer and Fiducials Before Hypofractionated External Beam Radiotherapy for Prostate Cancer.
Boissier R; Udrescu C; Rebillard X; Terrier JE; Faix A; Chapet O; Azria D; Devonec M; Paparel P; Ruffion A
Urology; 2017 Jan; 99():265-269. PubMed ID: 27725233
[TBL] [Abstract][Full Text] [Related]
8. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.
Mahal BA; Ziehr DR; Hyatt AS; Neubauer-Sugar EH; O'Farrell DA; O'Leary MP; Steele GS; Niedermayr TR; Beard CJ; Martin NE; Orio PF; D'Amico AV; Devlin PM; Nguyen PL
Brachytherapy; 2014; 13(5):442-9. PubMed ID: 24880584
[TBL] [Abstract][Full Text] [Related]
9. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
Patel AK; Houser C; Benoit R; Smith RP; Beriwal S
Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976
[TBL] [Abstract][Full Text] [Related]
10. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
12. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.
Hanlon AL; Watkins Bruner D; Peter R; Hanks GE
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497
[TBL] [Abstract][Full Text] [Related]
13. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
14. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
15. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients.
Prada PJ; Gonzalez H; Menéndez C; Llaneza A; Fernández J; Santamarta E; Ricarte PP
Brachytherapy; 2009; 8(2):210-217. PubMed ID: 19213607
[TBL] [Abstract][Full Text] [Related]
16. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.
Hamstra DA; Conlon AS; Daignault S; Dunn RL; Sandler HM; Hembroff AL; Zietman AL; Kaplan I; Ciezki J; Kuban DA; Wei JT; Sanda MG; Michalski JM;
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):546-53. PubMed ID: 23561651
[TBL] [Abstract][Full Text] [Related]
17. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results.
Prada PJ; Jimenez I; González-Suárez H; Fernández J; Cuervo-Arango C; Mendez L
Brachytherapy; 2012; 11(2):105-10. PubMed ID: 21917528
[TBL] [Abstract][Full Text] [Related]
19. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
20. Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer.
Stenmark MH; Conlon AS; Johnson S; Daignault S; Litzenberg D; Marsh R; Ritter T; Vance S; Kazzi N; Feng FY; Sandler H; Sanda MG; Hamstra DA
Radiother Oncol; 2014 Feb; 110(2):291-7. PubMed ID: 24507766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
